InvestSMART

Prescient Therapeutics Limited (ASX: PTX) - Announcements

Current share price for PTX : $0.067 0.001 (1.52%)+

ASX company news and announcements for Prescient Therapeutics Limited (PTX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Prescient Therapeutics Limited (PTX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Prescient Therapeutics Limited (PTX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Prescient Therapeutics Limited (PTX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$70 Update - Proposed issue of securities - PTX 15 Sep 2026 11:54AM $0.068 $0.067 fallen by 0.74%
$70 Prescient Therapeutics - Extension of Share Purchase Plan 15 Sep 2026 9:00AM $0.065 $0.067 risen by 3.08%
$70 Notice of Annual General Meeting/Proxy Form 14 Sep 2026 9:10AM $0.068 $0.067 fallen by 1.47%
$70 Update - Proposed issue of securities - PTX 8 Sep 2026 9:18AM $0.068 $0.067 fallen by 1.47%
$70 Prescient Therapeutics - Extension of Share Purchase Plan 8 Sep 2026 9:03AM $0.068 $0.067 fallen by 1.47%
$70 PTX-100 CTCL Phase 2a study reaches review milestone 2 Sep 2026 2:10PM $0.067 $0.067 fallen by 0%
$70 Prescient Share Purchase Plan Investor Presentation 26 Aug 2026 9:53AM $0.067 $0.067 fallen by 0%
$70 Prescient Therapeutics Opens SPP to Raise $7m Today 26 Aug 2026 8:57AM $0.067 $0.067 fallen by 0%
$70 Share Purchase Plan Cleansing Notice 26 Aug 2026 8:45AM $0.067 $0.067 fallen by 0%
$70 Proposed issue of securities - PTX 25 Aug 2026 2:47PM $0.066 $0.067 risen by 1.52%
$70 Prescient Therapeutics Launches Share Purchase Plan for $7m 25 Aug 2026 9:06AM $0.072 $0.067 fallen by 6.94%
$70 Appendix 4G and Corporate Governance Statement 21 Aug 2026 9:34AM $0.077 $0.067 fallen by 12.99%
$70 Appendix 4E and 2026 Annual Report 21 Aug 2026 9:32AM $0.077 $0.067 fallen by 12.99%
$70 June 2026 Quarterly Update and Appendix 4C 27 Jul 2026 12:36PM $0.087 $0.067 fallen by 22.99%
$70 Notification of cessation of securities - PTX 10 Jul 2026 2:53PM $0.072 $0.067 fallen by 6.94%
$70 PTX Dr Rosalind Wilson appointed as Chief Medical Officer 11 Jun 2026 10:03AM $0.065 $0.067 risen by 3.08%
$70 Response to ASX Price Query 15 May 2026 9:01AM $0.069 $0.067 fallen by 2.90%
$70 Investor Presentation 30 Apr 2026 9:37AM $0.051 $0.067 risen by 31.37%
$70 March 2026 Quarterly Update and Appendix 4C 30 Apr 2026 9:25AM $0.051 $0.067 risen by 31.37%
$70 Updated Securities Trading Policy 25 Feb 2026 9:03AM $0.063 $0.067 risen by 6.35%
$70 Appendix 4D and Half Year Financial Report 24 Feb 2026 5:00PM $0.063 $0.067 risen by 6.35%
$70 December 2025 Quarterly Update and Appendix 4C 30 Jan 2026 9:16AM $0.076 $0.067 fallen by 11.84%
$70 Notification regarding unquoted securities - PTX 19 Dec 2025 1:18PM $0.105 $0.067 fallen by 36.19%
$70 PTX secures EU Authorisation to commence PTX-100 Trial 15 Dec 2025 9:10AM $0.089 $0.067 fallen by 24.72%
$70 Change of Director's Interest Notice 21 Nov 2025 10:03AM $0.058 $0.067 risen by 15.52%

1 - 25 of 583 results

Page 1 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.